Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.

MLA

Rezk, Tamer, et al. “Cardiorenal AL Amyloidosis: Risk Stratification and Outcomes Based upon Cardiac and Renal Biomarkers.” British Journal of Haematology, vol. 186, no. 3, Aug. 2019, pp. 460–70. EBSCOhost, https://doi.org/10.1111/bjh.15955.

APA

Rezk, T., Lachmann, H. J., Fontana, M., Naharro, A. M., Sachchithanantham, S., Mahmood, S., Petrie, A., Whelan, C. J., Pinney, J. H., Foard, D., Lane, T., Youngstein, T., Wechalekar, A. D., Hawkins, P. N., & Gillmore, J. D. (2019). Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers. British Journal of Haematology, 186(3), 460–470. https://doi.org/10.1111/bjh.15955

Chicago

Rezk, Tamer, Helen J Lachmann, Marianna Fontana, Ana Martinez Naharro, Sajitha Sachchithanantham, Shameem Mahmood, Aviva Petrie, et al. 2019. “Cardiorenal AL Amyloidosis: Risk Stratification and Outcomes Based upon Cardiac and Renal Biomarkers.” British Journal of Haematology 186 (3): 460–70. doi:10.1111/bjh.15955.